Your browser doesn't support javascript.
loading
Heterogeneity of chronic graft-versus-host disease biomarkers: association with CXCL10 and CXCR3+ NK cells.
Kariminia, Amina; Holtan, Shernan G; Ivison, Sabine; Rozmus, Jacob; Hebert, Marie-Josée; Martin, Paul J; Lee, Stephanie J; Wolff, Daniel; Subrt, Peter; Abdossamadi, Sayeh; Sung, Susanna; Storek, Jan; Levings, Megan; Aljurf, Mahmoud; Arora, Mukta; Cutler, Corey; Gallagher, Geneviève; Kuruvilla, John; Lipton, Jeff; Nevill, Thomas J; Newell, Laura F; Panzarella, Tony; Pidala, Joseph; Popradi, Gizelle; Szwajcer, David; Tay, Jason; Toze, Cynthia L; Walker, Irwin; Couban, Stephen; Storer, Barry E; Schultz, Kirk R.
Afiliação
  • Kariminia A; Michael Cuccione Childhood Cancer Research Program, British Columbia Children's Hospital/University of British Columbia, Vancouver, BC, Canada;
  • Holtan SG; Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN;
  • Ivison S; Michael Cuccione Childhood Cancer Research Program, British Columbia Children's Hospital/University of British Columbia, Vancouver, BC, Canada;
  • Rozmus J; Michael Cuccione Childhood Cancer Research Program, British Columbia Children's Hospital/University of British Columbia, Vancouver, BC, Canada;
  • Hebert MJ; Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, University of Montreal, Montreal, QC, Canada;
  • Martin PJ; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA;
  • Lee SJ; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA;
  • Wolff D; Department of Internal Medicine III, University Hospital Regensburg, Regensburg, Germany;
  • Subrt P; Michael Cuccione Childhood Cancer Research Program, British Columbia Children's Hospital/University of British Columbia, Vancouver, BC, Canada;
  • Abdossamadi S; Michael Cuccione Childhood Cancer Research Program, British Columbia Children's Hospital/University of British Columbia, Vancouver, BC, Canada;
  • Sung S; Michael Cuccione Childhood Cancer Research Program, British Columbia Children's Hospital/University of British Columbia, Vancouver, BC, Canada;
  • Storek J; University of Calgary, Calgary, AB, Canada;
  • Levings M; Michael Cuccione Childhood Cancer Research Program, British Columbia Children's Hospital/University of British Columbia, Vancouver, BC, Canada;
  • Aljurf M; King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia;
  • Arora M; Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN;
  • Cutler C; Dana-Farber Cancer Institute, Boston, MA;
  • Gallagher G; Centre Hospitalier Universitaire de Quebec, Hopital Enfant-Jesus, Quebec City, QC, Canada;
  • Kuruvilla J; Princess Margaret Cancer Centre, Toronto, ON, Canada;
  • Lipton J; Princess Margaret Cancer Centre, Toronto, ON, Canada;
  • Nevill TJ; Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia, Vancouver, BC, Canada;
  • Newell LF; Center for Hematologic Malignancies, Knight Cancer Institute, Oregon Health & Science University, Portland, OR;
  • Panzarella T; Princess Margaret Cancer Centre, Toronto, ON, Canada;
  • Pidala J; H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;
  • Popradi G; McGill University Health Center, Montreal, QC, Canada;
  • Szwajcer D; CancerCare Manitoba, Winnipeg, MB, Canada;
  • Tay J; Ottawa Hospital Research Institute, Ottawa, ON, Canada;
  • Toze CL; Leukemia/Bone Marrow Transplant Program of British Columbia, Vancouver General Hospital, British Columbia Cancer Agency and University of British Columbia, Vancouver, BC, Canada;
  • Walker I; Hamilton Health Sciences and McMaster University, Hamilton, ON, Canada; and.
  • Couban S; Queen Elizabeth II Health Science Centre, Halifax, NS, Canada.
  • Storer BE; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA;
  • Schultz KR; Michael Cuccione Childhood Cancer Research Program, British Columbia Children's Hospital/University of British Columbia, Vancouver, BC, Canada;
Blood ; 127(24): 3082-91, 2016 06 16.
Article em En | MEDLINE | ID: mdl-27020088
ABSTRACT
Chronic graft-versus-host disease (cGVHD) remains one of the most significant long-term complications after allogeneic blood and marrow transplantation. Diagnostic biomarkers for cGVHD are needed for early diagnosis and may guide identification of prognostic markers. No cGVHD biomarker has yet been validated for use in clinical practice. We evaluated both previously known markers and performed discovery-based analysis for cGVHD biomarkers in a 2 independent test sets (total of 36 cases ≤1 month from diagnosis and 31 time-matched controls with no cGVHD). On the basis of these results, 11 markers were selected and evaluated in 2 independent replication cohorts (total of 134 cGVHD cases and 154 controls). cGVHD cases and controls were evaluated for several clinical covariates, and their impact on biomarkers was identified by univariate analysis. The 2 replications sets were relatively disparate in the biomarkers they replicated. Only sBAFF and, most consistently, CXCL10 were identified as significant in both replication sets. Other markers identified as significant in only 1 replication set included intercellular adhesion molecule 1 (ICAM-1), anti-LG3, aminopeptidase N, CXCL9, endothelin-1, and gelsolin. Multivariate analysis found that all covariates evaluated affected interpretation of the biomarkers. CXCL10 had an increased significance in combination with anti-LG3 and CXCL9, or inversely with CXCR3(+)CD56(bright) natural killer (NK) cells. There was significant heterogeneity of cGVHD biomarkers in a large comprehensive evaluation of cGVHD biomarkers impacted by several covariates. Only CXCL10 strongly correlated in both replication sets. Future analyses for plasma cGVHD biomarkers will need to be performed on very large patient groups with consideration of multiple covariates.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células Matadoras Naturais / Biomarcadores / Quimiocina CXCL10 / Receptores CXCR3 / Doença Enxerto-Hospedeiro Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Células Matadoras Naturais / Biomarcadores / Quimiocina CXCL10 / Receptores CXCR3 / Doença Enxerto-Hospedeiro Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies / Screening_studies Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article